| The price of innovation: new estimates of drug development costs | Journal of Health Economics | 2003 | 2.8K |
| Innovation in the pharmaceutical industry: New estimates of R&D costs | Journal of Health Economics | 2016 | 1.5K |
| Development trends for human monoclonal antibody therapeutics | Nature Reviews Drug Discovery | 2010 | 736 |
| Trends in risks associated with new drug development: success rates for investigational drugs | Clinical Pharmacology and Therapeutics | 2010 | 563 |
| The cost of biopharmaceutical R&D: is biotech different? | Managerial and Decision Economics | 2007 | 329 |
| Development trends for monoclonal antibody cancer therapeutics | Nature Reviews Drug Discovery | 2007 | 316 |
| Risks in new drug development: approval success rates for investigational drugs | Clinical Pharmacology and Therapeutics | 2001 | 297 |
| Economics of new oncology drug development | Journal of Clinical Oncology | 2007 | 271 |
| Recombinant protein therapeutics--success rates, market trends and values to 2010 | Nature Biotechnology | 2004 | 256 |
| Deconstructing the drug development process: the new face of innovation | Clinical Pharmacology and Therapeutics | 2010 | 241 |
| Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009 | Clinical Pharmacology and Therapeutics | 2011 | 236 |
| Monoclonal antibodies as innovative therapeutics | Current Pharmaceutical Biotechnology | 2008 | 194 |
| Antibody-based therapeutics to watch in 2011 | MAbs | 2011 | 184 |
| Returns on research and development for 1990s new drug introductions | Pharmacoeconomics | 2002 | 177 |
| Trends in development and approval times for new therapeutics in the United States | Nature Reviews Drug Discovery | 2003 | 171 |
| New drug development in the United States from 1963 to 1999 | Clinical Pharmacology and Therapeutics | 2001 | 167 |
| Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective | Clinical Pharmacology and Therapeutics | 1995 | 157 |
| The value of improving the productivity of the drug development process: faster times and better decisions | Pharmacoeconomics | 2002 | 148 |
| Monoclonal antibodies in the clinic | Nature Biotechnology | 2001 | 136 |
| Clinical approval success rates for investigational cancer drugs | Clinical Pharmacology and Therapeutics | 2013 | 126 |
| The economics of follow-on drug research and development: trends in entry rates and the timing of development | Pharmacoeconomics | 2004 | 124 |
| Assessing the impact of protocol design changes on clinical trial performance | American Journal of Therapeutics | 2008 | 102 |
| Development trends for new cancer therapeutics and vaccines | Drug Discovery Today | 2008 | 98 |
| Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry | Pharmacoeconomics | 1995 | 89 |
| ACTR-25. PHASE I/II STUDY OF TEMOZOLOMIDE PLUS NIMUSTINE CHEMOTHERAPY FOR RECURRENT MALIGNANT GLIOMAS: KYOTO NEURO-ONCOLOGY GROUP | Neuro-Oncology | 2017 | 78 |
